Mackenzie Financial
CNCE

Mackenzie Financial’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Mackenzie Financial’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,750
Closed -$160K – 1271
2018
Q3 		$160K Buy
+10,750
New +$169K ﹤0.01% 1079

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mackenzie Financial's CNCE Position: Q4 2018 in Review

Mackenzie Financial sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2018, closing a stake of 10,750 shares — an estimated $160K sold.

Mackenzie Financial first reported a position in CNCE in Q3 2018 and held it in 1 quarter. The position peaked at $160K in Q3 2018. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2018.

  • Mackenzie Financial reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Mackenzie Financial sold 10,750 Concert Pharmaceuticals, Inc. shares in Q4 2018, an estimated $160K.
  • Mackenzie Financial first reported a position in Concert Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Mackenzie Financial's Concert Pharmaceuticals, Inc. position peaked at $160K in Q3 2018.
  • 93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2018.

Based on Mackenzie Financial's 13F filing for Q4 2018, filed 6 Feb 2019.